Acelyrin – Talk Bio

Actionable Insights Powered by AI

Pliant and Acelyrin Adopt Poison Pill Defenses Against Potential Concentra Buyout

1 month ago talkbio0Tagged Acelyrin, Capital Partners, Concentra Biosciences, Contraceptives, Oral, Pliant, Poisons, Tang

Poison pill, Concentra Biosciences, Tang Capital Partners, Acelyrin, Pliant Therapeutics, hostile takeover defense

Acelyrin Rebuffs Concentra’s Acquisition Bid, Reaffirms Commitment to Alumis Merger

2 months ago talkbio0Tagged Acelyrin, Acquisition, all-stock, Alumis, Biological Factors, Concentra Biosciences, Immunology, Merger, Transaction

Acelyrin, Concentra Biosciences, Alumis, Merger, Acquisition offer, Immunology, Biopharmaceuticals, All-stock transaction

Concentra’s Surprise Bid Disrupts Acelyrin-Alumis Merger Plans

2 months ago talkbio0Tagged Acelyrin, Alumis, biopharmaceutical industry, Concentra Biosciences, Disruption, M&A, Merger, Unsolicited Adverse Event

Concentra Biosciences, Acelyrin, Alumis, merger disruption, unsolicited offer, biopharmaceutical industry, M&A

Acelyrin Reassesses Flagship Immunology Asset Izokibep Following Multiple Clinical Trial Setbacks

4 months ago talkbio0Tagged Acelyrin, Arthritis, Psoriatic, biotech, Clinical Trials, Failure (biologic function), Hidradenitis, Immunology, IPO, Izokibep, suppurativa

Acelyrin, Izokibep, Clinical Trial Failure, Immunology, Hidradenitis Suppurativa, Psoriatic Arthritis, Biotech IPO

Acelyrin Shifts Focus Amid Izokibep Setbacks, Lays Off Staff to Pursue Tepezza’s Market Share

8 months ago talkbio0Tagged Acelyrin, Clinical Trials, Izokibep, Market, setbacks, Strategy, Tepezza

Acelyrin, izokibep, clinical trial setbacks, layoffs, Tepezza, market strategy